Adult articular cartilage lacks significant regenerative capacity, and damage to this tissue often leads to progressive joint degeneration (osteoarthritis). We developed strategies to generate articular cartilage from human pluripotent stem cells (hPSCs) as a source of clinically relevant tissues for joint repair 1 . Previously, we demonstrated that these chondrocytes retain cartilage forming potential following subcutaneous implantation in mice. In this report, we evaluated the potential of human embryonic stem cell (hESC)-derived articular cartilage tissue to repair osteochondral defects created in the rat knee. Following implantation, the hESCderived cartilage maintained a proteoglycan and type II collagen-rich matrix, and was well integrated with native rat tissue at the basal and lateral surfaces. The ability to generate cartilage tissue with integrative and reparative properties from an unlimited and robust cell source represents a significant clinical advance for cartilage repair that can be applied to large animal models and ultimately to patient care.
Using serum-free directed differentiation methods previously described 1 , we generated articular cartilage-like tissue containing abundant proteoglycans (Safranin-O positive) and type II collagen but lacking type X collagen from the HES2-RFP hESC line which constitutively expresses red fluorescent protein (RFP, Figure 1A -D) 2 . We generated two osteochondral defects (1.45 mm diameter) in the trochlear groove of the rat femur, press-fitted size-matched biopsy punches of hESC-derived tissue into the defects, and sealed them with fibrin glue ( Figure 1E -F). Six to twelve weeks later, we assessed graft retention and cartilage quality compared to control defects treated with fibrin glue alone ( Figure 1G -H).
Eleven of the twenty-two defects analyzed after 6 weeks, and six of the eighteen defects analyzed at 12 weeks contained human cells/tissue. Absence of human cells in some of the defects was likely due to delamination of the tissue upon implantation, an inherent risk of this type of study 3 . Defects containing hESC-derived tissues contained significant regions of proteoglycan-and type II collagen-rich cartilage tissue after 6 and 12 weeks ( Figure 1I -P). In contrast, control defects generally lacked proteoglycans and type II collagen, but were enriched for type I collagen, indicating the presence of fibrocartilage-like tissue ( Figure 1R , T). Type I collagen was also present in host tissue at the periphery of the human tissue implant and at the articular surface ( Figure 1Q , S). Type X collagen, a marker of chondrocyte hypertrophy, was present in 5 of the 11 defects at 6 weeks and 1 of 6 defects at twelve weeks (representative defects shown in Figure 1U and 2F), with the highest levels localizing to the subchondral interface between implant and host tissue.
We quantified cartilage repair in defects receiving implants versus controls using a modified International Cartilage Repair Society (ICRS) II scoring system 4, 5 where 0 represents poor repair and 100 represents normal cartilage. The overall assessment scoring parameter was not significantly different between the defects receiving implants and controls after 6 weeks, but defects with human tissue scored significantly higher at 12 weeks ( Figure 1Y ). Implanted defects also had significantly higher scores in matrix staining, cell morphology, and middle/deep zone assessment at both 6 and 12 weeks. Scores for tidemark formation and vascularization significantly increased from 6 weeks to 12 week in defects receiving implants, while scores for matrix staining, cell morphology, middle/deep zone, and overall assessment significantly decreased in control defects over time ( Figure 1Z -BB, Supplementary Figures 1 and 2 ). These results indicate that cartilage repair quality was superior in defects receiving hESC-derived implants compared to those receiving fibrin glue alone.
Finally, we evaluated the responses of the implanted human tissue and the host rat tissue via histology. Implanted tissue was well integrated basally and laterally with host tissue at both time points ( Figure 2 ). Remodeling of human tissue typically occurred in areas that were exposed to the marrow cavity, similar to the process of endochondral bone formation 6 . Cells in these regions increased in size, alignment ( In this report we have demonstrated the ability of the hESC-derived articular cartilage tissues to engraft, persist and functionally integrate in an orthotopic site. The results of this study demonstrate that this is a viable approach for repairing damaged cartilage. Future studies in large animal models will explore the potential to treat osteochondral defects with a single hESC-derived cartilage implant.
Supplemental Material
Supplemental information including methods follows this manuscript. 
Supplemental Material Materials and Methods
Cell culture and tissue preparation Articular cartilage tissues were generated in serum-free conditions as described previously 1 from the HES2-RFP hESC line that constitutively expresses the red fluorescent protein (RFP) 2 . Briefly, hESCs (mycoplasma-free) were cultured as embryoid bodies for 3 days in the presence of Activin A, BMP4 and bFGF (R&D Systems) to induce early stage mesoderm formation. Chondrogenic mesoderm was induced in monolayer with an inhibitor of type I activin receptor-like kinase (ALK) receptors SB431542 (Sigma) (5.4 µM), bFGF (20 ng/ml) and the type I BMPR inhibitor Dorsomorphin (Sigma) (4 µM) until day 15. Cartilage tissues were generated in micromass format and cultured for an average of 14 weeks in chondrogenic media: high glucose DMEM (Gibco) supplemented with 1× ITS supplement (Gibco), ascorbic acid (Sigma) (50 µg/ml), proline (Sigma) (40 µg/ml) and dexamethasone (Sigma) (0.1 µM) and TGFβ3 (R&D Systems) (10 ng/ml).
Surgical procedure
All animal studies were approved by the Animal Resources Committee at University Health Network, Toronto, Ontario, Canada. Homozygous athymic nude rats (NIH nude rats, Crl:NIH-Foxn1 rnu ; rnu/rnu) were purchased from Charles River Laboratories and were provided with sterile housing. Surgeries were conducted on animals at eight to nine weeks of age. Animals were anesthetized under 5% isoflurane and maintained at 2% isofluorane during surgery. Buprenorphine (0.03 mg/kg) was used as an analgesic drug. Pre-operative and post-operative care was provided to animals according to the protocol.
The right knee area was shaved and cleaned with iodine surgical scrub (7.5% iodine), 70% isopropanol and 10% Providone iodine (equivalent to 1% iodine) in sequence. A longitudinal incision was made on the anterior aspect of knee with a surgical scalpel blade no.15 to expose the knee joint. The skin at medial and lateral side of knee joint was dislodged using two backward strokes with a pair of surgical scissors. A second cut was made on the knee joint medially on the muscle layer. The muscle layer along with the quadriceps tendon was pushed laterally to expose trochlear region of femur.
Two osteochondral defects (0.5 mm apart, one proximal, one distal) were created in the femoral trochlear groove with the help of a sorer (1.45 mm diameter, Fine Scientific Tools, Inc.). Animals were assigned at random to the experimental (implant) or control group. Size matched biopsy punches of hESC derived cartilage tissue were press-fitted into defects with the help of cotton gauze, and then sealed with fibrin glue (TISSEEL, Baxter). Control defects were filled with fibrin glue alone. A total of 26 control defects were created in 13 knees, hESC-derived cartilage tissue was implanted into 40 defects in 20 knees.
The muscle layer was reverted back to the medial side and quadriceps tendon was placed in its original position. The medial muscle layer was sutured discontinuously at three points with 5-0 Polysorb TM suture (Covidien * ). The skin was closed using intradermal continuous suturing using MONOCRYL * suture (Ethicon), and glued with a thin layer of tissue adhesive (Vetbond, 3M). Following surgery, animals were monitored according to approved animal protocol, and then permitted to move freely for 6 or 12 weeks.
Tissue Retrieval and Histology
Immediately following euthanasia, the knee joints were excised, and the defects were exposed and imaged macroscopically. Whole joints were then fixed in 10% neutral buffered formalin (Sigma) and decalcified for approximately ten days in Immunocal Decalcifier solution (DECAL Company) with changes every three days before being processed for paraffin embedding and histological analyses. Sagittal sections (5 µm thickness) of the trochlear groove of the femur containing defect(s) were stained with 0.1% Safranin O (Electron Microscopy Sciences) and counterstained with Weigert's haematoxylin (Electron Microscopy Sciences) and 0.02% fast green (Electron Microscopy Sciences). Immunohistochemistry was used to visualize type I (Sigma), II (clone 6B3 EMD Millipore) and X collagen (Clone X53, Quartett, Germany) and red fluorescent protein (ab34771, Abcam). The M.o.M™ (Mouse on Mouse) Detection Kit (Vector Laboratories Inc.) was used with the type I and type II collagen monoclonal antibodies to minimize background staining. Detection was performed using VECTASTAIN ABC and DAB reagents (Vector Laboratories Inc.). Sections were counterstained with Meyers
